Market Overview

UPDATE: Piper Jaffray Initiates ZIOPHARM Oncology at Neutral on 2013 Cancer Development Outlook

Related ZIOP
ZIOPHARM, Intrexon Offer Clinical, Preclinical Data from Immuno-Oncology Programs: Showed Anti-Cancer Activity, Planning Phase 1b/@ Trial AD-RTS-HIL-12 with Veledimex
Mid-Afternoon Market Update: Dow Rises Over 150 Points; Kohl's Shares Decline On Weak Forecast

Piper Jaffray initiated coverage on ZIOPHARM Oncology (NASDAQ: ZIOP) with a Neutral rating and a $5.00 price target.

Piper Jaffray said, "The company's management deploys its considerable oncology network to focus on developing improved chemotherapeutics, and we believe its lead candidate palifosfamide (pali', DNA-alkylator), will succeed in at least one indication based on clinical rationale and early data. Pali' is currently in two Phase III studies, for 1st-line soft tissue sarcoma (STS) and for 1st-line small-cell lung cancer (SCLC). That said, we are not sufficiently convinced by the stated PFS-driven regulatory strategy to make a call on the near term pivotal PFS data in STS."

ZIOPHARM Oncology closed at $4.18 on Thursday.

Latest Ratings for ZIOP

DateFirmActionFromTo
Mar 2014Piper JaffrayUpgradesUnderweightNeutral
Apr 2013JefferiesSuspendsHold
Mar 2013Brinson PatrickDowngradesOutperformMarket Perform

View More Analyst Ratings for ZIOP
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ZIOP)

Around the Web, We're Loving...

Get Benzinga's Newsletters